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Abstract
Background: The beneficial effects of bilateral sub-thalamic nucleus deep brain stimulation on motor function and
gait in advanced Parkinson’s disease are established. Less is known about the effect of stimulation on cognitive
function and the capacity to walk while dual tasking, an ability that has been related to fall risk. Everyday walking
takes place in complex environments that often require multi-tasking. Hence, dual tasking gait performance reflects
everyday ambulation as well as gait automaticity. The purpose of this study was to examine the impact of sub-
thalamic nucleus deep brain stimulation on dual task walking in patients with advanced Parkinson’s disease.
Methods: Gait was assessed using a performance-based test and by quantifying single-task and dual task walking
conditions in 28 patients with advanced Parkinson’s disease. These tests were conducted in 4 conditions: “OFF”
medication, with the stimulator turned on and off, and “ON” medication, with the stimulator turned on and off. A
previously validated, computerized neuro-psychological battery assessed executive function, attention and memory
“OFF” and “ON” deep brain stimulation, after subjects took their anti-Parkinsonian medications.
Results: Stimulation improved motor function and the spatiotemporal parameters of gait (e.g., gait speed) during
both single-task and dual task walking conditions. Attention improved, but executive function did not. The dual
task effect on gait did not change in response to stimulation. For example, during serial 3 subtractions, gait
speed was reduced by -0.20 ± 0.14 m/sec while OFF DBS and OFF meds and by −0.22±0.14 m/sec when the
DBS was turned on (p=0.648). Similarly, ON medication, serial 3 subtractions reduced gait speed by −0.20±0.16 m/sec
OFF DBS and by -0.22±0.09 m/sec ON DBS (p=0.543).
Conclusions: Bilateral sub-thalamic nucleus deep brain stimulation improves motor symptoms, certain features of gait
and even some aspects of cognitive function. However, stimulation apparently fails to reduce the negative impact of a
dual task on walking abilities. These findings provide new insight into the effects of deep brain stimulation on gait
during cognitively challenging conditions and everyday walking.
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Background
In patients with advanced Parkinson’sd i s e a s e ,s u b -
thalamic nucleus (STN) deep brain stimulation (DBS)
reduces tremor, rigidity and bradykinesia, allows for a
significant decrease in anti-Parkinsonian medications,
and diminishes dyskinesias [1-4]. Indeed, pre-surgery
Unified Parkinson’s Disease Rating Scale (UPDRS)
motor scores may often be improved by two-thirds in
response to DBS [2-5]. DBS also enhances postural
control and increases gait speed and stride length, both
off and on anti-Parkinsonian medications [6-9]. From
this perspective, DBS appears to provide good relief for
key motor symptoms of advanced PD.
The effects of DBS on the ability to walk while
performing a dual task (DT) have not been previously
studied. Everyday walking typically takes place in complex
environments and challenging situations that demand
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simultaneously-performed additional tasks such as talking
on a cellphone [10,11]. Thus, whereas single-task walking
represents the capabilities of a patient, DT walking
abilities more closely reflect functional ambulation in
cognitively-demanding conditions. DT walking abilities
also provide a window into the automaticity of movement
[10,12]. Over-learned movements do not depend on atten-
tion or cognitive input and are generally impervious to the
effects of dual tasking. For example, healthy young adults
can walk and perform other tasks with little impact on
their gait. Conversely, when gait is impaired or relies on
cognitive input, a DT will cause marked changes in the
walking pattern. The simultaneous performance of a DT
generally causes patients with PD to walk more slowly,
with shorter strides, and with a much larger effect of the
DT on gait than seen in healthy controls [11,13-16]. Pilot
studies have demonstrated that interventions may enhance
DT abilities even in PD [17-20], however, the effects of
STN DBS on DTgait have not yet been investigated.
A priori, there are several ways to view the impact of
DBS on DT walking. One possibility is that the negative
DT effects, i.e., the DTcosts, might be reduced as a result
of DBS due to the improved motor function. If walking
becomes a more automatic process after DBS and walking
capacity improves, then it should be more resistant and
impervious to the negative effects of DT. In other words,
DBS should improve functional reserve so that it is less
vulnerable to the effects of a DT. Alternatively, although
gait improvement does occur in response to DBS, not all
aspects of gait respond similarly to DBS [21-25]; for
example, freezing of gait typically does not respond well to
traditional STN DBS [26]. From this perspective, perhaps
those gait properties that are more critical to DT abilities
will not be enhanced. The effects of DBS on cognitive
function are inconsistent, with some studies even
reporting a decline in executive function following DBS
[2,27,28]. Since DT abilities are also related to cognitive
abilities, especially executive function [10,29], it could be
speculated that DBS might not ameliorate the DTcosts.
The primary purpose of the present study was to
address these questions by quantifying the DT effects
on gait in patients with PD while ON and OFF DBS. We
hypothesized that STN DBS (ON DBS) reduces the DT
costs of gait, compared to the costs observed when the
stimulator is off (OFF DBS). To investigate the effects of
DBS in a state that more closely reflects the underlying
pathology, we examined the subjects during the OFF
medication state. To evaluate conditions that reflect
everyday function, patients were also assessed in the
ON state (ON, OFF meds and ON and OFF DBS).
Analysis focused on two properties of gait: 1) average
stride length (and the closely related average gait speed).
Stride length and gait speed are widely accepted
measures of mobility in general [30], and in PD specific-
ally [31,32]. 2) measures of gait variability. These gait
features reflect the rhythmicity and consistency of the
gait pattern, are altered in PD, are related to disease se-
verity, and are related to fall risk [15,33-37]. Because of
the potential role of cognitive function in DT costs, we
also quantified the effects of DBS on this domain to gain
insight into the relationship between the STN, cognitive
function, and DTabilities in patients with advanced PD.
Methods
Participants
Subjects were included if they fulfilled UK Brain Bank
criteria for PD [38], if they had undergone bilateral STN
DBS surgery at least two months prior to the study for
treatment of PD symptoms, if their stimulation settings
were stable, and if they could walk independently with-
out any walking aids, with the DBS on. Standard clinical
criteria were used to evaluate the subjects for their suit-
ability for STN DBS surgery. Selection criteria that were
applied are those that have become widely accepted in
many parts of the world. This includes, for example, at
least a 30% improvement in UPDRS scores in response
to an l-dopa challenge; a diagnosis of idiopathic PD for
at least 4 or more years; complications of medication in-
cluding ON-OFF fluctuations and/or dyskinesias; normal
brain MRI; and otherwise generally healthy. Psychiatric
exclusions include sub-optimally controlled depression.
Psychotic patients are automatically excluded. To be ap-
proved for DBS surgery, the patients undergo a battery
of cognitive tests. Addenbrooke’s Cognitive Examination
(ACE) is used as a cognitive screen (subjects are included
if they score over 70), along with the Frontal Assessment
Battery (FAB), for which we generally will require a score
of at least 12. The Hamilton Depression Rating Scale
(HDRS) is used to screen for depression; subjects who
score more than 15 will be excluded or sent for more
detailed evaluation. Frank dementia is obviously an exclu-
sion factor. Between 50% and 70% of patients who are re-
ferred to our center for surgery meet accepted inclusion
criteria. The institutional review board (IRB) of Hadassah
University Hospital approved this study and informed
written consent was obtained.
Protocol
Subjects arrived for the assessment in the morning, at
least 12 hours after taking their last anti-Parkinsonian
medication dose, i.e., in an OFF meds/ON DBS state,
when medication effects are minimal [39,40]. While OFF
medications, they were familiarized with the gait and dual
tasks. Subjects then completed gait testing, the Timed Up
and Go test, and the motor part of the UPDRS, both ON
and OFF DBS. Subjects then took their usual morning
dose of anti-Parkinsonian medications. After reaching a
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later), gait, the Timed Up and Go, and the motor part of
the UPDRS were re-evaluated. A neuropsychological bat-
tery quantified cognitive function both ON and OFF DBS,
while ON meds. The order of testing (ON vs. OFF DBS),
was randomized both while OFF medications and while
ON medications. With ample breaks, the entire protocol
typically took about 3 hours to complete.
Gait tasks
Gait was studied in three conditions: 1) “single-task”,
usual-walking at a self-selected comfortable speed (ST
walking), 2) walking while subtracting serial 3s from a
predefined 3 digit number (DT-S3) and 3) walking while
performing a verbal fluency task (DT-VF) (without explicit
instructions regarding prioritization); they were asked to
recite words that began with a specific letter (the letter
was randomized across conditions), using a previously val-
idated protocol [41,42]. To determine if the effects of DBS
on DT gait were dependent on the specifics of the dual
task, both the arithmetic and fluency tasks were used. The
order of testing (ST, DT-S3, and DT-VF) was randomized.
Under each condition, subjects walked up and down an 18
meter-long, 2-meter wide hallway at their self-selected
speed for one minute.
Secondary tasks
In each medication/DBS condition, serial subtraction
(using a different 3 digit starting number) was also
performed for one minute in the seated position to allow
for quantification of the effects of walking on these cogni-
tive tasks. The order of testing, i.e., seated vs. walking, was
randomized. To minimize testing time, verbal fluency was
not tested in the seated position. For both secondary tasks,
the number of errors and number of words or subtrac-
tions were scored to evaluate performance on the serial
subtraction and verbal fluency tests.
For each walking condition, several gait measures
were derived from force sensitive shoe insoles and a
stopwatch, using previously described and validated
methods [14,15,19]. Briefly, steady-state gait speed was
calculated by measuring the time to complete the
middle 10 meters of each lap, averaged over all laps for
each walk. Additional gait parameters that were evalu-
ated included: average stride length, average stride time,
average swing time, and gait variability, as measured by
stride time variability and swing time variability [14,15,19].
Stride time was defined as the time from initial foot con-
tact to the next initial foot contact. Swing time, presented
as a percent of the gait cycle, was defined as the time of
single support; it is determined by the time from toe-off to
heel-strike, divided by the stride time (×100) and
presented as a percent of the gait cycle (for healthy young
adults, swing time % is about 40% of the gait cycle).
Variability was defined using the coefficient of variation,
e.g., 100 × (standard deviation of stride time)/(average
stride time). Using previously described methods, the data
at each turn (that took place when the subject reached the
end of a lap) and any data during freezing of gait episodes,
were excluded from the analysis. Any freezing of gait epi-
sode was counted in each walking condition. To compare
the DT effects across DBS and medication states, the DT
cost measure was calculated as the difference between the
single-task and DT walking conditions, for each gait par-
ameter [10,11]. We also verified that the results were simi-
lar if DT costs were calculated as percent change instead
of the difference. Since both methods of estimating DT
costs produced similar findings, only the results based on
the differences are reported.
Assessment of PD symptoms and cognitive function
PD status and disease severity were evaluated using the
motor portion of the UPDRS [43]. Mean L-dopa daily
dose was quantified as previously described [44]. The
Timed Up and Go test assessed functional mobility
[45,46] (standard instructions were followed; there was
no dual task during this test). A computerized neuro-
psychological test battery (Mindstreams
W, NeuroTrax
Corp., NJ), previously validated in patients with PD
[15,47] quantified executive function, memory and
attention (largely sustained attention) [48,49]. The
executive function battery included computerized
versions of the Go-No-Go and the Stroop interference
tests. The test battery generates composite indices of
each cognitive domain [48-50] on an IQ-like scale, with
100 representing the estimated population mean nor-
malized for age and education.
Statistical analysis
Descriptive statistics are reported as mean± standard
deviation. Many of the dependent variables were not
normally distributed; hence, non-parametric analyses
were applied since they make no assumptions about
the distribution of the data and are not sensitive to
extreme values. To assess the effects of DBS on gait,
Friedman’s tests (the non-parametric parallel to repeated
measures ANOVA) were first applied for each gait
parameter (e.g., gait speed) to determine if any of the
walking conditions differed from one another (i.e., ST,
Table 1 Subject characteristics (n =28)
Age (years) 61.46± 8.13
Gender 3 females
Disease duration (years) 13.2± 5.0
Mini Mental State Exam 27.9± 1.7
Time after surgery (months) 25.4±13.1
UPDRS motor scores (OFF DBS/OFF meds) 38.53±13.53
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Wilcoxon Signed Rank tests were applied to determine
which conditions differed. Similar analyses were applied
to the cognitive measures, other patient characteristics,
and to the DT costs. P-values reported are based on
two-tailed comparisons. The significance level was set
at 0.05. Statistical analyses were performed using SPSS
for Windows.
Results
Subject characteristics
In a consecutive sample spanning from October 2007 to
November 2008, 28 patients with PD met the inclusion
and exclusion criteria and agreed to participate. Patient
characteristics are summarized in Table 1 and Table 2.
Stimulation parameters included a mean rate of 161.96±
24.01 Hz for the left or the right side. The mean voltage
was 3.08±0.58 V for the right side and 3.12±0.61 V for
the left side. Pulse width was 90 μs for 10 electrodes (in 6
patients) and 60 μs for the other 46 electrodes. Mean
L-dopa daily dose was 1180±758 mg before surgery and
490±269 mg after surgery (p<0.001); with a median
decrease in medication dose of 60% (Dopa-equivalent).
Effects of DBS on motor function and single-task walking
UPDRS motor scores improved significantly (p<0.0001)
with DBS stimulation (both ON and OFF meds), and
when comparing the two extreme states (i.e., OFF meds/
OFF DBS vs. ON meds/ON DBS) as seen in Table 2.
Similarly, Timed Up and Go times decreased (i.e., im-
proved) in response to DBS, both ON meds (p =0.007)
and OFF meds (p=0.001). Timed Up and Go duration
in the ON meds/ON DBS condition was significantly
lower than that in the OFF meds/OFF DBS condition.
Table 2 summarizes the single-task walking parameters
in the 4 medication/DBS conditions. Gait speed im-
proved in response to DBS in the OFF meds condition
(p=0.009). In the ON meds condition, gait speed also
tended to improve, but this increase was not significant
(p=0.053). Gait speed and stride length in the ON
meds/ON DBS condition were significantly greater than
those in the OFF meds/OFF DBS condition. Stride time
variability improved (i.e., decreased) in response to DBS
in the OFF meds condition, however, this change did not
reach the level of significance (p=0.093). Swing time
variability significantly improved in response to DBS in
the ON meds condition (p =0.035).
Effects of DBS on DT costs
Both dual tasks (serial subtractions and verbal fluency)
had a significant negative impact on almost all gait
parameters in all 4 conditions, compared to single-task
walking (typically p<0.0001 under every condition, for
all gait parameters). For example, in the OFF meds/OFF
DBS condition, gait speed was reduced from 1.01±
0.30 m/sec during single-task walking to 0.84±0.29 m/sec
Table 2 Effects of DBS on motor symptoms and single-task, usual-walking gait
OFF meds ON meds
OFF DBS ON DBS P-value OFF vs. ON DBS OFF DBS ON DBS P-value OFF vs. ON DBS
UPDRS Motor part 38.53±13.53 17.5±8.20 <0.001 36.20±13.84 13.40±7.82* <0.001
Timed Up and Go (sec) 14.97± 5.69 12.62±4.42 0.001 13.28±3.27 11.46±2.35* 0.007
Gait speed (m/s) 1.01±0.30 1.09±0.31 0.009 1.13±0.19 1.21± 0.18* 0.053
Stride length (m) 1.09±0.29 1.16±0.30 0.005 1.27±0.14 1.32± 0.15* 0.049
Stride time (sec) 1.10±0.12 1.090± .10 0.502 1.09±0.10 1.09± 0.10 0.653
Stride time variability (%) 2.82±1.42 2.33±1.24 0.093 2.19±0.91 1.84± 0.46* 0.407
Swing time (%) 36.19± 3.09 36.18±2.68 0.654 36.66±2.87 36.90±2.05 0.199
Swing time variability (%) 5.35±3.10 4.65±2.81 0.156 4.68±2.02 3.94± 1.20 0.035
*indicates a significant difference between OFF meds/OFF DBS vs. ON meds/ON DBS.
Table 3 Effects of DBS on dual task costs during serial 3 subtractions*
OFF meds ON meds
OFF DBS ON DBS P-value OFF vs. ON DBS OFF DBS ON DBS P-value OFF vs. ON DBS
Gait speed (m/sec) −0.20±0.14 −0.22±0.14 0.648 −0.20±0.16 −0.22± 0.09 0.543
Stride length (m) −0.16±0.09 −0.16±0.11 0.823 −0.17±0.10 −0.15± 0.11 0.778
Stride time (sec) 0.08±0.11 0.08± 0.10 0.433 0.07± 0.10 0.09±0.10 0.398
Stride time variability (%) 0.62±0.81 0.84± 0.95 0.067 2.09± 3.17 1.01±0.91 0.243
Swing time (%) −1.09±1.07 −0.93±0.91 0.247 −1.21±1.63 −0.81± 1.00 0.904
Swing time variability (%) 1.70±1.44 1.78± 1.48 0.502 2.33± 3.97 1.19±1.62 0.355
*Entries are single-task - dual task values.
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0.28 m/sec (p<0.0001) during the verbal fluency task.
In the ON meds/ON DBS condition, gait speed was
reduced from 1.08 ±0.32 m/sec during single-task
walking to 0.91±0.29 m/sec during serial 3 subtrac-
tions (p <0.0001), and to 0.87±0.30 m/sec during the
verbal fluency task (p <0.0001).
As summarized in Tables 3 and 4, the DT cost of all
gait parameters did not change with stimulation com-
pared to the DT cost without stimulation, when subjects
were ON or OFF medications (see also Figure 1). The
DT costs in the two extreme conditions (i.e., OFF meds/
OFF DBS and the ON meds/ON DBS) were also not
significantly different from each other for all gait
parameters. As noted in the Methods, the lack of any
beneficial effect of DBS on DT costs was also observed
if costs were determined as percent change. For example,
for gait speed, the percent change in each of the 4 condi-
tions, corresponding to those in Table 3, were: -20.67% and
-23.20% (P= 0.848, DBS effect OFF meds) and −16.38%
and −20.20% (P=0.778, DBS effect ON meds) during serial
subtractions. Table 4 summarizes the effects of DBS on
dual costs during the verbal fluency task. As was the case
for serial subtraction, the DTcost of all gait parameters did
not change with stimulation compared to the DT cost
without stimulation, during the verbal fluency task.
Performance of secondary tasks
Tables 5 and 6 summarize the performance of the second-
ary tasks in all 4 walking conditions. Briefly, in response to
Table 4 Effects of DBS on dual costs during the verbal fluency task*
OFF meds ON meds
OFF DBS ON DBS P-value OFF vs. ON DBS OFF DBS ON DBS P-value OFF vs. ON DBS
Gait speed (m/sec) −0.21±0.10 −0.20±0.08 0.615 −0.22±0.12 −0.22± 0.09 0.681
Stride length (m) −0.17±0.08 −0.16±0.07 0.903 −0.16±0.07 −0.15± 0.07 0.494
Stride time (sec) 0.10±0.12 0.07± 0.07 0.181 0.10± 0.13 0.08±0.10 0.520
Stride time variability (%) 0.61±1.29 1.18± 1.73 0.192 1.61± 1.99 1.23±1.46 0.687
Swing time (%) −1.01±1.20 −1.13±1.03 0.689 −1.23±1.30 −1.45± 2.66 0.658
Swing time variability (%) 1.82±1.59 2.00± 2.44 0.958 2.60± 3.80 3.36±8.63 0.573
*Entries are single-task - dual task values.
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Figure 1 The effects of DBS on dual costs on gait speed (left) and stride length (right) for the serial 3 subtraction (above) and verbal
fluency tasks (below). For visual purposes, costs are displayed as a positive number (i.e., dual task value – single-task value). Note that if these
analyses were repeated after stratifying by time since surgery, the findings were essentially unchanged; for example, among the subjects who
more than 12 months after surgery, there were no changes in DT costs (p>0.463).
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walking was unchanged OFF medications (p=0.796). ON
medications, the number of serial subtractions increased
(p=0.036). The number of mistakes made was not related
to medication or DBS condition (see Table 6). Verbal flu-
ency performance was also independent of medication
and DBS condition.
Effects of DBS on freezing of gait
Freezing of gait (FOG) was observed in 9 subjects. FOG
occurred in 12% of the walking tasks. The vast majority
of the freezing (79%) took place during the turns at the
end of each lap, i.e., only about 3% of the walks were
interrupted by FOG in the middle of a lap. The number
of FOG episodes was not significantly affected by DBS.
For example, in the OFF medication condition (p>0.18
overall), 3 episodes occurred during usual walking, both
ON and OFF DBS. 4 episodes took place during serial 3
subtractions OFF DBS and 6 occurred ON DBS. Two
FOG episodes occurred during the verbal fluency dual
task off DBS, while 4 occurred when DBS was on.
Effects of DBS on cognitive function
Figure 2 shows the cognitive index scores both ON and
OFF DBS (while ON meds). Attention improved in re-
sponse to DBS and executive function improved, however,
the increase was not statistically significant. Memory did
not improve in response to DBS. Interestingly, improve-
ments in the executive function index in response to DBS
were associated with lower (i.e., better) DT costs for stride
length during the verbal fluency task (r=0.65, p=0.032)
(see Figure 3). Similarly, improvements in the executive
function index in response to DBS were associated with
lower (i.e., better) DT costs for stride time variability
during the serial 3 subtraction task (r=0.66, p=0.038).
Discussion
STN DBS has previously been associated with improve-
ments in motor function, stride length, gait speed and
rhythmicity [6-9]. We, therefore, hypothesized that gait
would be more consistent and automatic and less cogni-
tively demanding when the stimulation was activated and
that this effect would lead to a reduction in the DT costs
of gait, compared to the costs observed when the stimula-
tor is off. Our findings suggest that this hypothesis should
be rejected. Although we found improvement in certain
features of single-task gait and cognitive function with
stimulation, the impact of DT on gait was unchanged in
response to bilateral STN DBS.
One partial explanation might be that the effects of
DBS on cognitive function were not sufficient or specific
enough to elicit beneficial changes to DT walking. We
found improvement in attention with STN stimulation,
although executive function did not improve signifi-
cantly. The attention index that we used largely reflects
sustained attention, but not task switching or dual
tasking. Executive function may be more closely associ-
ated with DT performance and complex everyday walk-
ing in PD [10,11,51]. While executive function did
respond to DBS in some subjects and there was an asso-
ciation between improvement in this cognitive domain
and DT costs (recall Figure 3), this finding was not con-
sistently observed. Thus, this overall negative finding
with respect to executive function might explain the lack
of improvement in DT walking ability. Improvements in
single-task gait alone are apparently not sufficient to
lower the DT impact as some form of cognitive reserve
Table 5 Performance on secondary tasks: number of subtractions (S3) and verbal fluency (VF)
OFF meds ON meds*
OFF DBS ON DBS P-value OFF vs. ON DBS OFF DBS ON DBS P-value OFF vs. ON DBS
S3 Sitting 16.09± 7.84 17.77±8.23 0.055 16.77±9.12 17.50±8.56 0.830
S3 Walking 15.61± 7.77 15.66±8.07 0.796 15.05±7.75 17.94±8.27 0.036
P-Value Sitting vs. Walking 0.659 0.001 0.157 0.311
VF Walking 6.26±3.14 6.47± 1.92 0.732 6.66± 2.19 6.77±2.57 0.855
*Entries are the mean± standard deviation number of words recited in each condition for verbal fluency and the mean ± standard deviation number of
subtractions during the serial 3 subtraction task.
Table 6 Performance on secondary tasks: mistakes in the number of subtractions or while generating words
OFF meds ON meds
OFF DBS ON DBS P-value OFF vs. ON DBS OFF DBS ON DBS P-value OFF vs. ON DBS
S3 Sitting 1.04±1.09 0.90± 1.06 0.476 0.88±1.13 0.94±0.99 0.803
S3 Walking 1.33±1.13 1.44± 1.38 0.750 1.31±1.70 1.42±1.64 0.677
P-Value Sitting vs. Walking 0.408 0.694 0.239 0.770
VF Walking 0.52±0.84 0.89± 0.87 0.109 0.27±0.57 0.72±1.12 0.190
S3: serial 3 subtractions; VF: verbal fluency.
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with PD [12]. This observation that only specific sub-
domains of cognitive function improved in response to
DBS is consistent with previous studies [27,52]. Interest-
ingly, Alberts et al. [53] reported that bilateral STN DBS
leads to a decreased ability to track forces when the dual
task was complex (e.g., serial 3 subtractions), somewhat
parallel to the influence of serial subtractions on gait in
the present study.
The basal ganglia have multiple connections to frontal
networks that regulate executive function and cognitive
abilities [54,55]. The present findings are consistent with
previous studies that suggested that STN DBS does not
positively influence these circuits and their function
[2,27,28]. In addition to the basal ganglia-thalamocortical
motor circuits, output from the basal ganglia also ends in
the pedunculopontine nucleus (PPN), an area which has
been termed the brain’s gait pace regulator [56-58]. Noting
the ineffectiveness of STN DBS to reduce fall risk and
freezing of gait, consistent with the present findings, sev-
eral authors speculated that PPN stimulation may be more
successful for ameliorating axial symptoms like freezing
and falls [26,44,58]. In the future, it would be interesting
to test whether DTcosts respond to PPN stimulation.
Clinical implications and limitations
Falls and freezing of gait, common causes of falls in PD,
are, typically, unresponsive to STN DBS [21,28,58,59].
Weaver et al. even describe an increase in fall frequency
post-DBS among patients with PD [60]. It is unclear if
this increase is a direct effect of DBS or an indirect
result [60]. Improved ambulation following DBS may
lead to greater exposure to challenging situations and,
hence, to an increased risk of falls. Among older adults
and in patients with PD, many falls occur during ambula-
tion and fall risk has been related to executive function,
DT performance, gait variability, and usual-walking gait
abilities [15,42,51,61-69]. In the present study, usual-
75
80
85
90
95
Memory Executive Functions Attention
OFF DBS
ON DBS
P=0.03 P=0.65 P=0.19
Figure 2 Differences in cognitive function index scores between ON and OFF DBS (while ON medications).
Figure 3 Scatter plot showing the relationship between the change in executive function and change in DT stride length costs during
the verbal fluency task in response to DBS (ON medications) (r=0.65, p= 0.032). In general, subjects who had better executive function
scores in response to DBS also had lower DT costs (plotted as a positive change).
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these other fall risk factors were generally not responsive
to DBS. If subjects walk faster after DBS, while their
cognitive function and ability to cope with challenging
conditions are unchanged, as reflected in the DT costs,
perhaps they have a greater risk for falls. In this regard,
it is interesting to note that the present findings suggest
that just as patients with PD inappropriately focus their
attention on the secondary, dual tasks and apply a
“posture second” strategy [12,16], this poor judgment is
not responsive to DBS.
This study has several limitations. For example, the
assessment protocol was long (approximately 3 hours)
and some subjects became tired toward the end. This
may have resulted in an under-estimation of the effects
of anti-Parkinsonian medication, as the assessments with
medication were always conducted last, when the sub-
jects were most likely to be tired. On the other hand,
this situation may actually reflect everyday abilities.
Similarly, we did not assess the response to a supra-
maximal dose of l-dopa, something that might be of inter-
est in the future, because we aimed to focus on testing that
reflects the subject’s typical abilities and medication
dosing. We also did not make any statistical corrections
for multiple comparisons. However, this analytical choice
actually increased the likelihood that we might find
support for lower DTcosts in response to DBS; the results
did not support this possibility, even though both dual
tasks generally had robust (e.g., p<0.001) negative effects
on gait. Another limitation is that the assessor was not
blinded to the condition. However, data analyses were
performed offline using automated software routines that
were blinded to the conditions. Finally, we did not include
a healthy control group to compare the DT costs. How-
ever, previous studies reported higher DT costs among
patients with PD compared to age-matched controls
[11,15]. We, therefore, conjecture that the costs observed
in the present study were also larger than those that could
be expected to be seen in healthy controls.
Conclusions
The present investigation is, to our knowledge, the first
explicit examination of DT walking in PD patients after
STN DBS. The DT costs of multiple, distinct aspects of
gait did not improve in response to STN DBS. The
absence of change in this ability with STN stimulation
indicates that this surgery does not positively impact on
the automaticity of walking and suggests that PD
patients may be unable to adequately cope with the
multi-tasking challenges that are common during every-
day walking. Several interventions have been proposed
for reducing the impact of DT on gait in PD [17-20]; it
would, in the future, be of interest to examine if these
are effective in post-DBS patients.
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